Home
PTCT
PTCT News

Latest PTC Therapeutics Inc. (PTCT) News on November 2, 2025

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

PR Newswire

12 days ago

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a month ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Shares in PTC Therapeutics Soared This Week

Motley Fool

2 months ago

Here's Why Shares in PTC Therapeutics Soared This Week

MT Newswires

4 months ago

PTC Therapeutics Says European Commission Grants it Marketing Authorization for Sephience

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

PR Newswire

4 months ago

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches

Insider Monkey

4 months ago

Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

4 months ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy

Zacks

5 months ago

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy

MT Newswires

5 months ago

RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating

This week in Trumponomics: Too bad TACO isn’t true

Yahoo Finance

5 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

The Guardian

5 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Yahoo Finance Video

5 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Reuters

5 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

USA TODAY

5 months ago

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Simply Wall St.

5 months ago

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Saturday Sessions: OK Go performs "Love"

CBS News Videos

5 months ago

Saturday Sessions: OK Go performs "Love"

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

Simply Wall St.

5 months ago

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

Those who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51%

Simply Wall St.

5 months ago

Those who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51%

PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential

Insider Monkey

6 months ago

PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential

MT Newswires

6 months ago

BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55

MT Newswires

6 months ago

Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50

Associated Press Finance

6 months ago

PTC Therapeutics: Q1 Earnings Snapshot

MT Newswires

6 months ago

PTC Therapeutics Swings to Q1 Earnings, Revenue Increases

PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

6 months ago

PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

PR Newswire

6 months ago

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

PTC Therapeutics price target lowered to $57 from $65 at RBC Capital

TipRanks

6 months ago

PTC Therapeutics price target lowered to $57 from $65 at RBC Capital

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

Benzinga

6 months ago

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

MT Newswires

6 months ago

RBC Capital Adjusts PTC Therapeutics Price Target to $57 From $65, Maintains Outperform Rating

Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result

GuruFocus.com

6 months ago

Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result

MT Newswires

6 months ago

Sector Update: Health Care Stocks Decline Pre-Bell Monday

PTC stock slides on new data for Huntington’s drug

BioPharma Dive

6 months ago

PTC stock slides on new data for Huntington’s drug

MT Newswires

6 months ago

PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint

PTC518 PIVOT-HD Study Achieves Primary Endpoint

PR Newswire

6 months ago

PTC518 PIVOT-HD Study Achieves Primary Endpoint

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

6 months ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Zacks

6 months ago

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

MT Newswires

6 months ago

PTC Therapeutics Says Potential Phenylketonuria Drug Receives EU Panel's Positive Opinion

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

PR Newswire

6 months ago

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

PTC Therapeutics to Participate at Upcoming Investor Conferences

PR Newswire

6 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?

Zacks

7 months ago

PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

PR Newswire

7 months ago

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

MT Newswires

7 months ago

RBC Lifts Price Target on PTC Therapeutics to $65 From $64, Keeps Outperform Rating

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

7 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

7 months ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

Sector Update: Health Care Stocks Mixed Friday Afternoon

MT Newswires

7 months ago

PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

PR Newswire

7 months ago

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

PR Newswire

7 months ago

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Zacks

8 months ago

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.

8 months ago

PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon

Simply Wall St.

8 months ago

We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon

Thomson Reuters StreetEvents

8 months ago

Q4 2024 PTC Therapeutics Inc Earnings Call

MT Newswires

8 months ago

RBC Capital Adjusts PTC Therapeutics Price Target to $64 From $63, Maintains Outperform Rating

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

GuruFocus.com

8 months ago

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

8 months ago

PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

Zacks

8 months ago

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

MT Newswires

8 months ago

PTC Therapeutics Q4 Loss Narrows; Sets Guidance -- Shares Fall After-Hours

Associated Press Finance

8 months ago

PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire

8 months ago

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

8 months ago

PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings

Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Zacks

8 months ago

Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

8 months ago

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics to Participate in Upcoming Investor Conferences

PR Newswire

8 months ago

PTC Therapeutics to Participate in Upcoming Investor Conferences

MT Newswires

8 months ago

PTC Therapeutics Says FDA Grants Priority Review to Vatiquinone NDA for Treating Friedreich's Ataxia; Shares Up Pre-Bell

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PR Newswire

8 months ago

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

MT Newswires

8 months ago

RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

PR Newswire

9 months ago

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald

TipRanks

9 months ago

PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

Zacks

9 months ago

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

Why PTC Therapeutics (PTCT) Stock Is Rallying Today

Insider Monkey

9 months ago

Why PTC Therapeutics (PTCT) Stock Is Rallying Today

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

10 months ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire

10 months ago

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

10 months ago

RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire

10 months ago

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

10 months ago

PTC Therapeutics Files NDA With US FDA for Vatiquinone to Treat Friedreich's Ataxia

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

PR Newswire

10 months ago

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a year ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Morgan Stanley Upgrades PTC Therapeutics to Overweight From Equalweight, Raises Price Target to $67 From $45

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

Investor's Business Daily

a year ago

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug

Investor's Business Daily

a year ago

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug

PTC Therapeutics price target raised to $71 from $47 at UBS

TipRanks

a year ago

PTC Therapeutics price target raised to $71 from $47 at UBS

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

Zacks

a year ago

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Zacks

a year ago

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

MT Newswires

a year ago

UBS Raises PTC Therapeutics Price Target to $71 From $47, Maintains Buy Rating

MT Newswires

a year ago

RBC Upgrades PTC Therapeutics to Outperform From Sector Perform, Raises Price Target to $63 From $39

Novartis and PTC Therapeutics link to develop Huntington’s therapy

Pharmaceutical Technology

a year ago

Novartis and PTC Therapeutics link to develop Huntington’s therapy

MT Newswires

a year ago

Sector Update: Health Care Stocks Slipping Late Afternoon

MT Newswires

a year ago

Sector Update: Health Care

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

Benzinga

a year ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Investopedia

a year ago

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

GuruFocus.com

a year ago

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate

MT Newswires

a year ago

PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone

Investor's Business Daily

a year ago

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PR Newswire

a year ago

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTC Therapeutics to sell Priority Review Voucher for $150M

TipRanks

a year ago

PTC Therapeutics to sell Priority Review Voucher for $150M

PTC Therapeutics ALS drug fails to meet endpoints as trials shut down

Clinical Trials Arena

a year ago

PTC Therapeutics ALS drug fails to meet endpoints as trials shut down

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Benzinga

a year ago

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

MT Newswires

a year ago

PTC Therapeutics to Sell Rare Pediatric Disease Voucher for $150 Million

Share on Social Networks: